AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.
Location: United States, Maryland, Baltimore
Employees: 11-50
Total raised: $10M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Johns Hopk... | ventures.j... |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.09.2017 | - | $10M | - |
Mentions in press and media 13
| Date | Title | Description |
| 25.08.2023 | Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds | Most available treatments for neurological disease act broadly across the brain, including in unwanted regions that cause intolerable side effects. Rapport Therapeutics — a clinical-stage biotech that was founded last year — is seeking to s... |
| 13.09.2019 | AgeneBio receives $3.4M for development of Alzheimer’s treatment | Baltimore-based AgeneBio received over $3 million in new grant funding as the company looks to make progress with a pair of treatments for conditions related to Alzheimer’s disease. AgeneBio works on treatments to slow Mild Cognitive Impair... |
| 19.07.2019 | Role of seizures in Alzheimer’s disease is gaining overdue attention | Scientists who study Alzheimer’s disease have mostly ignored the role of seizures, but that is beginning to change, and new research suggests they may provide insight into the progression of the disease and pave the way for treatments. It’s... |
| 11.10.2018 | AgeneBio gets grants to advance therapeutics to slow Alzheimer’s disease | Baltimore-based AgeneBio announced a pair of grants from the National Institutes of Health that will assist with clinical trials of a treatment to combat the progression of Alzheimer’s disease. The awards from the NIH’s National Institute o... |
| 13.09.2017 | AgeneBio to Receive up to $10 Million in NIH Funding | AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced it has been awarded a grant for up to $10 million from the National Institute on Aging (NIA) of the Nati... |
| 17.09.2015 | This JHU startup is working on a treatment to prevent Alzheimer’s | A Johns Hopkins startup received a federal grant to enter trials of its treatment for a brain disease that often precedes Alzheimer’s disease. AgeneBio and Johns Hopkins received a five-year grant from the National Institutes of Health that... |
| 18.03.2015 | Red Owl Analytics lands investment from Blackstone [Startup Roundup] | WHO’S GETTING FUNDED Personal Genome Diagnostics won a contract from the U.S. Department of Veterans Affairs’ Integrated Service Network in New England, according to a news release. The Canton-based biotech company will provide DNA testing ... |
| 09.02.2015 | Citelighter teams up with Encyclopedia Britannica [Startup Roundup] | WHO’S GETTING FUNDED Biotech continues to attract a lot of money to Baltimore. Over the last week, a pair of local companies got sizable grants to boost their Baltimore operations. Emergent Biosolutions received a $2 million grant from the ... |
| 24.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $4.1 million in equity raised of a proposed $10 million According to Phase IIa trials, its drug – levetiracetam – is showing promise in treating the mild cognitive decline that often results in Alzheimer’s. The drug’s usually used to treat ... |
| 06.01.2012 | Alzheimer’s disease treatment uses anti-seizure meds to slow memory loss | For its lead product, the company is repurposing an existing anti-seizure medication to prevent the progression of amnestic mild cognitive impairment (aMCI) to Alzheimer’s disease. It’s using the drug as a neural stabilizer to normalize exc... |
Show more